“As blockbusters go off patent and the pool of marketed products supporting pharmaceutical Research & Development (R&D) decline, questions about the future of R&D in the pharmaceutical and biotech industry arise. Where will funding come from? Is spend decreasing? If spend is decreasing, what impact is this having on R&D? What can be done to encourage innovation in the biotech and pharmaceutical industry? Is the biotech model of R&D better for innovation than the traditional pharmaceutical model?
Gauging the overall growth of R&D in the pharmaceutical and biotech industry proves challenging in regards to stipulating the appropriate definition of variables by which this is measured. Public companies may release overall expenses, yet allocations to specific products or franchises may be more difficult to assess. On a related note, information may be available about specific research projects and molecules under development, yet tying those back to the overall R&D expenses can also be challenging. To that end, we are focused on general estimations in this report which address a high level analysis of the overall industry and a basic formulaic approach to understanding growth and productivity within R&D. The methods used for assessing these variables are supported by literature in the field.
Research & Development (R&D) in the Pharmaceutical and Biotech Industry has experienced a major shift from the blockbuster era of the last decade. Pharmaceutical manufacturers are operating with thinner margins and smaller pipelines, the success rates of early stage research projects have decreased, and overall the complexity of efficient and productive R&D in the pharmaceutical industry has increased. This report provides an overview of the current situation in pharmaceutical and biotech R&D.
Please Note: This product is delivered as a zip file
– Current scenario of R&D
– Review of the pipeline and key issues affecting R&D efforts
– Approvals by year and by...